Comparative effectiveness of pegcetacoplan versus ravulizumab in patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab: a matching-adjusted indirect comparison

References

• Brodsky RA. Stem cell transplantation for paroxysmal nocturnal hemoglobinuria. Haematologica. 2010;95(6):855–856.
   PubMed Web of Science ®Google Scholar
• Jalbert JJ, Chaudhari U, Zhang H, et al. Epidemiology of PNH and real-world treatment patterns following an incident PNH diagnosis in the US. Blood. 2019;134(Supplement_1):3407–3407.
   Web of Science ®Google Scholar
• Brodsky RA, Young NS, Antonioli E, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood. 2008;111(4):1840–1847.
   PubMed Web of Science ®Google Scholar
• Hill A, Hillmen P, Richards SJ, et al. Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria. Blood. 2005;106(7):2559–2565.
   PubMed Web of Science ®Google Scholar
• Hillmen P, Elebute M, Kelly R, et al. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. Am J Hematol. 2010;85(8):553–559.
   PubMed Web of Science ®Google Scholar
• Hillmen P, Muus P, Duhrsen U, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood. 2007;110(12):4123–4128.
   PubMed Web of Science ®Google Scholar
• Hillmen P, Muus P, Roth A, et al. Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2013;162(1):62–73.
   PubMed Web of Science ®Google Scholar
• Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355(12):1233–1243.
   PubMed Web of Science ®Google Scholar
• Alexion Pharmaceuticals, Inc. Ultomiris [prescribing information]. Boston (MA): Alexion Pharmaceuticals, Inc.; 2018.
   Google Scholar
• Kulasekararaj AG, Hill A, Rottinghaus ST, et al. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. Blood. 2019;133(6):540–549.
   PubMed Web of Science ®Google Scholar
• Lee JW, Sicre de Fontbrune F, Wong Lee Lee L, et al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood. 2019;133(6):530–539.
   PubMed Web of Science ®Google Scholar
• DeZern AE, Dorr D, Brodsky RA. Predictors of hemoglobin response to eculizumab therapy in paroxysmal nocturnal hemoglobinuria. Eur J Haematol. 2013;90(1):16–24.
   PubMed Web of Science ®Google Scholar
• Brodsky RA. Paroxysmal nocturnal hemoglobinuria. Blood. 2014;124(18):2804–2811.
   PubMed Web of Science ®Google Scholar
• McKinley CE, Richards SJ, Munir T, et al. Extravascular hemolysis due to C3-Loading in patients with PNH treated with eculizumab: defining the clinical syndrome. Blood. 2017;130(Supplement 1):3471–3471.
   Google Scholar
• Nakayama H, Usuki K, Echizen H, et al. Eculizumab dosing intervals longer than 17 days may be associated with greater risk of breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria. Biol Pharm Bull. 2016;39(2):285–288.
   PubMed Web of Science ®Google Scholar
• Peffault de Latour R, Fremeaux-Bacchi V, Porcher R, et al. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. Blood. 2015;125(5):775–783.
   PubMed Web of Science ®Google Scholar
• Hillmen P, Szer J, Weitz I, et al. Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2021;384(11):1028–1037.
   PubMed Web of Science ®Google Scholar
• de Castro C, Grossi F, Weitz IC, et al. C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab. Am J Hematol. 2020;95(11):1334–1243.
   PubMed Web of Science ®Google Scholar
• Phillippo D, Ades A, Dias S, et al. NICE DSU technical support document 18: methods for population-adjusted indirect comparisons in submissions to NICE. Decision Support Unit, ScHARR, University of Sheffield: NICE Decision Support Unit; 2016.
   Google Scholar
• Jang JH, Okamoto S, Sakurai M, et al. Comparison of baseline clinical characteristics between Asian Vs. Non-Asian patients with paroxysmal nocturnal hemoglobinuria (PNH) from international PNH registry. Blood. 2017;130(Supplement 1):3472–3472.
   Google Scholar
• Sakurai M, Jang JH, Chou WC, et al. Comparative study on baseline clinical characteristics of Asian versus non-Asian patients with paroxysmal nocturnal hemoglobinuria. Int J Hematol. 2019;110(4):411–418.
   PubMed Web of Science ®Google Scholar
• Signorovitch JE, Sikirica V, Erder MH, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012;15(6):940–947.
   PubMed Web of Science ®Google Scholar
• Barcellini W, Fattizzo B. Clinical applications of hemolytic markers in the differential diagnosis and management of hemolytic anemia. Dis Markers. 2015;2015:635670.
   PubMed Web of Science ®Google Scholar
• Risitano AM, Marotta S, Ricci P, et al. Anti-complement treatment for paroxysmal nocturnal hemoglobinuria: time for proximal complement inhibition? A position paper from the SAAWP of the EBMT. Front Immunol. 2019;10:1157.
   PubMed Web of Science ®Google Scholar
• Schrezenmeier H, Muus P, Socie G, et al. Baseline characteristics and disease burden in patients in the international paroxysmal nocturnal hemoglobinuria registry. Haematologica. 2014;99(5):922–929.
   PubMed Web of Science ®Google Scholar
• Lee JW, Jang JH, Kim JS, et al. Clinical signs and symptoms associated with increased risk for thrombosis in patients with paroxysmal nocturnal hemoglobinuria from a Korean registry. Int J Hematol. 2013;97(6):749–757.
   PubMed Web of Science ®Google Scholar
• Jang JH, Kim JS, Yoon SS, et al. Predictive factors of mortality in population of patients with paroxysmal nocturnal hemoglobinuria (PNH): results from a Korean PNH registry. J Korean Med Sci. 2016;31(2):214–221.
   PubMed Web of Science ®Google Scholar
• Yenerel MN, Muus P, Wilson A, et al. Clinical course and disease burden in patients with paroxysmal nocturnal hemoglobinuria by hemolytic status. Blood Cells Mol Dis. 2017;65:29–34.
   PubMed Web of Science ®Google Scholar
• Cella D, Eton DT, Lai J-S, Peterman AH, et al. Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage. 2002;24(6):547–561.
   PubMed Web of Science ®Google Scholar
• Cella D, Lai J, Chang CH, et al. Fatigue in cancer patients compared with fatigue in the general United States population. Cancer. 2002;94(2):528–538.
   PubMed Web of Science ®Google Scholar
• Snyder CF, Blackford AL, Sussman J, et al. Identifying changes in scores on the EORTC-QLQ-C30 representing a change in patients’ supportive care needs. Qual Life Res. 2015;24(5):1207–1216.
   PubMed Web of Science ®Google Scholar
• Scott NW, Fayers PM, Aaronson NK, et al. EORTC QLQ-C30 reference values. Brussels (Belgium): EORTC Quality of Life Group; 2008.
   Google Scholar
• Cheng D, Ayyagari R, Signorovitch J. The statistical performance of matching-adjusted indirect comparisons. 2019: arXiv:1910.06449. [cited 2019 Oct 1]. https://ui.adsabs.harvard.edu/abs/2019arXiv191006449C.
   Google Scholar